He Jian, Huo Yu, Zhang Zhikun, Luo Yiqun, Liu Xiuli, Chen Qiaoying, Wu Pan, Shi Wei, Wu Tao, Tang Chao, Wang Huixue, Li Lan, Liu Xiyu, Huang Yong, Zhao Yongxiang, Gan Lu, Wang Bing, Zhong Liping
National Center for International Research of Biotargeting Theranostics, Guangxi Key Laboratory of Biotargeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Biotargeting Theranostics, Guangxi Medical University, Nanning 530021, China.
The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning 530023, China.
Acta Pharm Sin B. 2022 Jul;12(7):3177-3186. doi: 10.1016/j.apsb.2022.03.002. Epub 2022 Mar 9.
Hepatocellular carcinoma (HCC) is a common malignant tumor with poor prognosis and high mortality. In this study, we demonstrated a novel vaccine targeting HCC and tumor neovascular endothelial cells by fusing recombinant MHCC97H cells expressing porcine -1,3-galactose epitopes (Gal) and endorphin extracellular domains (END) with dendritic cells (DCs) from healthy volunteers. END/Gal-MHCC97H/DC fusion cells induced cytotoxic T lymphocytes (CTLs) and secretion of interferon-gamma (IFN-). CTLs targeted cells expressing Gal and END and tumor angiogenesis. The fused cell vaccine can effectively inhibit tumor growth and prolong the survival time of human hepatoma mice, indicating the high clinical potential of this new cell based vaccine.
肝细胞癌（HCC）是一种常见的恶性肿瘤，预后差且死亡率高。在本研究中，我们通过将表达猪α-1,3-半乳糖表位（Gal）和内啡肽细胞外结构域（END）的重组MHCC97H细胞与健康志愿者的树突状细胞（DC）融合，展示了一种靶向HCC和肿瘤新生血管内皮细胞的新型疫苗。END/Gal-MHCC97H/DC融合细胞诱导细胞毒性T淋巴细胞（CTL）并分泌γ干扰素（IFN-γ）。CTL靶向表达Gal和END的细胞以及肿瘤血管生成。这种融合细胞疫苗可有效抑制肿瘤生长并延长人肝癌小鼠的存活时间，表明这种新型细胞疫苗具有很高的临床潜力。
